Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Blood (2024) 144 (Supplement 1): 1031.

https://doi.org/10.1182/blood-2024-198499

Published: 2024

Journal Articles

Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023

Adeel M Khan, Zimu Gong, Tanushree Prasad, Rahul Banerjee, Srija Shankar, Aimaz Afrough, Larry D Anderson, Jr., Meera Mohan, Gurbakhash Kaur

Blood (2024) 144 (Supplement 1): 3792.8.

https://doi.org/10.1182/blood-2024-210930

Published: 2024

Journal Articles

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 3765.

https://doi.org/10.1182/blood-2024-199609

Published: 2024

Journal Articles

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Lauren C. Peres, Alicia Richards, Surbhi Sidana, Laura B. Oswald, Danai Dima, Aimaz Afrough, Leyla O. Shune, Shonali Midha, Omar Castaneda, Christopher Ferreri, James A Davis, Oren Pasvolsky, Christen M. Dillard, Megan M Herr, Mehmet H. Kocoglu, Shebli Atrash, Brandon Blue, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Gurbakhash Kaur, Mahmoud R. Gaballa, Peter A. Forsberg, Ciara Louise Freeman, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Djordje Atanackovic, Binod Dhakal, Jack Khouri, Shahzad Raza, Ran Reshef, Melissa Alsina, Frederick L. Locke, Omar Nadeem, Faiz Anwer, Larry D Anderson, Jr., Shambavi Richard, Yi Lin, Thomas Martin, Peter M. Voorhees, Krina K. Patel, Doris K. Hansen, Douglas W Sborov

Blood (2024) 144 (Supplement 1): 3785.

https://doi.org/10.1182/blood-2024-210078

Published: 2024

Journal Articles

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Blood (2024) 144 (Supplement 1): 3337.

https://doi.org/10.1182/blood-2024-206357

Published: 2024

Journal Articles

Dexamethasone Is Associated with Cataracts in Multiple Myeloma Even after Adjusting for Age: Results of a Large Cross-Sectional Survey

Rahul Banerjee, Jorge Arturo Hurtado Martinez, Mason S. Barnes, Patricia Alejandra Flores Pérez, Jay R. Hydren, Jennifer M. Ahlstrom, Kara I. Cicero, Gurbakhash Kaur, Parisa Taravati, Andrew J. Cowan

Blood (2024) 144 (Supplement 1): 7828.

https://doi.org/10.1182/blood-2024-201803

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 897.

https://doi.org/10.1182/blood-2024-203409

Published: 2024

Journal Articles

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards, Leyla O. Shune, Aimaz Afrough, Shonali Midha, Binod Dhakal, Mehmet H. Kocoglu, Shebli Atrash, Chris Ferreri, Omar Castaneda, James A Davis, Evguenia Ouchveridze, Joseph P. McGuirk, Charlotte B Wagner, Radhika Bansal, Patrick Costello, Kinaya Smith, Alex Lieberman-Cribbin, Gabriel De Avila, Sneha Purvey, Hitomi Hosoya, Lekha Mikkilineni, Laura B. Oswald, Gurbakhash Kaur, Oren Pasvolsky, Mahmoud R. Gaballa, Megan M Herr, Peter A. Forsberg, Murali Janakiram, Myo Htut, Sireesha Asoori, Nilesh Kalariya, Hamza Hashmi, Ran Reshef, Douglas W Sborov, Omar Nadeem, Faiz Anwer, Jack Khouri, Shahzad Raza, Djordje Atanackovic, Melissa Alsina, Ciara Louise Freeman, Frederick L. Locke, Peter M. Voorhees, Larry D Anderson, Jr., Shambavi Richard, Thomas Martin, Yi Lin, Krina K. Patel, Surbhi Sidana

Blood (2024) 144 (Supplement 1): 936.

https://doi.org/10.1182/blood-2024-194390

Published: 2024

Journal Articles

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Blood (2024) 144 (Supplement 1): 934.

https://doi.org/10.1182/blood-2024-205989

Published: 2024

Journal Articles

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Blood (2024) 144 (Supplement 1): 6874.

https://doi.org/10.1182/blood-2024-201755

Published: 2024

Journal Articles

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Sharlene Dong, Ankit J. Kansagra, Gurbakhash Kaur, Anna Barcellos, Andrew J. Belli, Laura L. Fernandes, Eric Hansen, Jacob Ambrose, Claire Bai, Christina M. Zettler, Ching-Kun Wang

Blood (2023) 142 (Supplement 1): 5145.

https://doi.org/10.1182/blood-2023-180263

Published: 2023

Journal Articles

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Blood (2023) 142 (Supplement 1): 6921.

https://doi.org/10.1182/blood-2023-186596

Published: 2023

Journal Articles

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Sharlene Dong, Heather Reves, Yu-Lun Liu, Radhika Kainthla, Aimaz Afrough, Julio Alvarenga, Larry D. Anderson, Jr., Stephen S. Chung, Robert H. Collins, Gurbakhash Kaur, Adeel Khan, Kiran Achut Kumar, Yazan F. Madanat, Heather R Wolfe, Elif Yilmaz, Farrukh T. Awan, Praveen Ramakrishnan Geethakumari

Blood (2023) 142 (Supplement 1): 2417.

https://doi.org/10.1182/blood-2023-188033

Published: 2023

Journal Articles

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

Rahul Banerjee, Gurbakhash Kaur, Bo Wang, Larry D. Anderson, Jr., Georgia McCaughan, Andrew J. Cowan, S. Vincent Rajkumar

Blood (2023) 142 (Supplement 1): 5073.

https://doi.org/10.1182/blood-2023-173772

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Danai Dima, Aishwarya Sannareddy, Nausheen Ahmed, James A Davis, Hira Shaikh, Zahra Mahmoudjafari, Marissa Duco, Jack Khouri, Gurbakhash Kaur, Jonathan Lochner, Faiz Anwer, Aimaz Afrough, Jason Valent, Hamza Hashmi, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2023-180458

Published: 2023

Journal Articles

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Danai Dima, James A Davis, Nausheen Ahmed, Aishwarya Sannareddy, Hira Shaikh, Zahra Mahmoudjafari, Jack Khouri, Gurbakhash Kaur, Christopher Strouse, Jason Valent, Larry D. Anderson, Jr., Faiz Anwer, Al-Ola Abdallah, Hamza Hashmi

Blood (2023) 142 (Supplement 1): 91.

https://doi.org/10.1182/blood-2023-180421

Published: 2023

Journal Articles

Demographic Characteristics and Treatment Patterns in Veterans with Multiple Myeloma: A Comprehensive Analysis from the Veterans Affairs Database (2000-2020)

Gurbakhash Kaur, Aishwarya Sannareddy, Aaron Perkins, Hui Yang, Somtochukwu Egbuonu, Adeel Khan, Aimaz Afrough, Ankit Kansagra, Larry D. Anderson, Jr., Carlos Alvarez

Blood (2023) 142 (Supplement 1): 7370.

https://doi.org/10.1182/blood-2023-189965

Published: 2023

NARROW

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial

Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023

Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium

Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel

Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab

Dexamethasone Is Associated with Cataracts in Multiple Myeloma Even after Adjusting for Age: Results of a Large Cross-Sectional Survey

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma

Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium

Screening for AL Amyloidosis in Smoldering Multiple Myeloma

Validation of a Composite Real-World Mortality Variable Among Patients with Hematologic Malignancies Treated in the United States

Incidence of Invasive Fungal Infections in CAR T-Cell Therapy Recipients: A Single-Center Retrospective Analysis

Utilization and Barriers to Stem Cell Transplantation in Relapsed/Refractory Hodgkin Lymphoma: A ‘Real-World’ Study of Treatment Patterns and Outcomes at a Safety-Net Versus a Tertiary Academic Hospital

Standard-of-Care Bortezomib Dosing in Multiple Myeloma: An International Survey of Physicians

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Toxicity and Efficacy Outcomes of Teclistamab in Patients with Relapsed-Refractory Multiple Myeloma (RRMM) Above the Age of 70 Years: A Multicenter Study

Real-World Safety and Efficacy of Teclistamab for Patients with Heavily Pretreated Relapsed-Refractory Multiple Myeloma

Demographic Characteristics and Treatment Patterns in Veterans with Multiple Myeloma: A Comprehensive Analysis from the Veterans Affairs Database (2000-2020)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only